← Leaderboards
En Huang
Univ Of Arkansas For Med Scis
$1,885,170
Attributed
$1,885,170
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $740K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,885,170 · 2
By mechanism
R01$1,468,670 · 1
R21$416,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Carbapenem Resistance”
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$11,832,144
- Terry Roemer · Prokaryotics, Inc.$8,492,492
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$6,918,682
- Eili Ya'akov Klein · Center/ Disease Dynamics, Econom/Policy$5,496,137
- Graig Shockey · Dynport Vaccine Company, Llc$5,167,891
- David A. Rosen · Washington University$4,614,307
Research focus
Carbapenem ResistanceMembraneGram-Negative BacteriaMedicalPredispositionResistanceDrug Resistant PathogenEscherichia ColiIn VitroAntimicrobialMulti-Drug ResistancePathogenPublic HealthReportingAntibiotic ResistanceAcinetobacter BaumanniiBacterial InfectionsAntibioticsAntibiotic TherapyInfectionCarbapenemaseKlebsiella PneumoniaeAreaAntimicrobial Resistance
Grant awards (5)
Mechanisms of cefiderocol nonsusceptibility and resistance evolution in carbapenem-resistant pathogens$739,974
R01 · FY2025 · AI · contact PI
Mechanisms of cefiderocol nonsusceptibility and resistance evolution in carbapenem-resistant pathogens$1
R01 · FY2025 · AI · contact PI
Mechanisms of cefiderocol nonsusceptibility and resistance evolution in carbapenem-resistant pathogens$728,695
R01 · FY2024 · AI · contact PI
Novel linear lipopeptide paenipeptins sensitize multidrug-resistant Gram-negative pathogens to antibiotics$190,000
R21 · FY2020 · AI · contact PI
Novel linear lipopeptide paenipeptins sensitize multidrug-resistant Gram-negative pathogens to antibiotics$226,500
R21 · FY2019 · AI · contact PI